Sunitinib Malate Market

Sunitinib Malate Market: Global Size, Trends, Competitive, Historical & Forecast Analysis, 2019-2025. Rising occurrence of pancreatic cancer, the convenience of a less drug therapeutic selections for the treatment of advanced pancreatic neuroendocrine tumors and poor diagnosis rate in the early phases of pancreatic cancer are some key drivers for Global Sunitinib Malate Market.

Scope of Global Sunitinib Malate Market:

 Sunitinib Malate is the small molecule, orally bioavailable malate salt of an indolinone-based multi-targeted receptor tyrosine kinase (RTK) inhibitor that was approved by the Food and Drug Administration (FDA) for the treatment of Carcinoma. Sunitinib Malate is having molecular formula C22H27FN4O2 so molecular weight is 398.482 g/mol. The possible antineoplastic activity of Sunitinib has managed to it being observed as an effective agent in inhibiting cell proliferation and angiogenesis. Sunitinib capsules have been approved for use in treatment of Pancreatic Neuroendocrine Tumors, Kidney Cancer and Gastrointestinal Stromal Tumor (GIST).

Mechanism of action of Sunitinib Malate is it prevents cellular signaling by targeting multiple receptor tyrosine kinases (RTKs). Sunitinib Malate also inhibits CD117 (c-KIT), the receptor tyrosine kinase that drives the many gastrointestinal stromal cell tumors. The side effects of Sunitinib Malate are Diarrhea, Heartburn, Hypertension, fatigue, Nausea and Vomiting, skin discoloration, cough, upset stomach, hair loss, fever, abdominal pain, shortness of breath, watery eyes, numbness or tingling of the arms or legs and swelling around the eyes.

Global Sunitinib Malate Market has been segmented on the basis of Application and Geography. On the basis of Application Global Sunitinib Malate Market is classified into Pancreatic Neuroendocrine Tumors, Advanced Kidney Cancer, Gastrointestinal stromal tumor (GIST) and others.

The regions covered in Global Sunitinib Malate Market report are North America, Europe, Asia-Pacific and Rest of the World. On the basis of country level, Global Melanoma Drug Market sub divided in to U.S., Mexico, Canada, U.K., France, Germany, Italy, China, Japan, India, South East Asia, GCC, Africa, etc.

Sunitinib Malate Market Key Players:

• Pfizer
• Topcare pharmaceutical Co. Ltd
• Nanjing First Pharmaceutical Co. Ltd.
• J&K Scientific
• Target Molecule Corp.
• Medichem
• Biotechnica Pharma Global
• Beijing Lunarsun Pharmaceutical Co. LTD
• Brawn Laboratories Ltd INDIA
• Hetero Drugs Ltd INDIA
• Hikma Pharmaceutical plc
• Jeil Pharmaceutical Co. Ltd
• Natco Pharma LTD
• Reliance Life Sciences Pvt. Ltd
• Shilpa Medicare Ltd INDIA
• Sichuan Xieli Pharmaceutical Co LTD
• Synthland Ltd and Teva Pharmaceutical Industries Ltd.
• JandK Scientific
• Astellas Pharma Inc.
• Bristol-Myers Squibb Company
• Natco Pharma LTD.
• Others

Sunitinib Malate Market Segmentation:

By Application:

• Pancreatic Neuroendocrine Tumors
• Advanced Kidney Cancer
• Gastrointestinal stromal tumor (GIST)
• Other

Market Dynamics:

Rising incidence of pancreatic neuroendocrine tumors, pancreatic cancer is a main driver for the Global Sunitinib Malate Market. Likewise, accessibility of an inadequate number of drug therapeutics for the treatment of advanced pancreatic neuroendocrine tumors and poor diagnosis rate in the initial phases of pancreatic cancer is increasing the demand of Sunitinib Malate in the treatment of pancreatic cancer. Conversely high cost of Sutent is one of the key restraints of the Global Sunitinib Malate Market growth. For 28 capsules of Sutent 37.5mg average cash price is $17,968.99. Some side effects of Sutent such as Hepatotoxicity and Adverse cardiovascular events like heart failure, myocardial infarction and coronary artery bypass grafting have also been reported during clinical trials, which could discourage adoption of the drug. Increase in awareness about the disease and technological expansions are likely to raise the Global Sunitinib Malate Market. Also Rising Prevalence of Cancer, Increase in Pharmaceutical R&D Spending, Rising Healthcare Expenditure and Rising Asian Population will boost the Global Sunitinib Malate Market. Systematic Drugs under Pipeline, Rising Scope for Cancer Therapy and increasing awareness towards Carcinoma are some opportunities in the forecast period for the Global Sunitinib Malate Market.

Regional Analysis:

North America holds the largest share of Global Sunitinib Malate Market amongst others. It is mainly driven by quickly increasing incidence of pancreatic cancer.  Moreover the incomes of customers and health insurance cover for life-threatening diseases in U.S. are very high which raises the affordability of cancer treatment. In recent years, US Food and Drug Administration (USFDA) has taken initiatives to support the progress of cancer drugs market by providing pre-market approval to the drugs, which are in the clinical phase therefore hastening the clinical development. Asia-Pacific is likely to grow vastly in the future due to some factors such as high occurrence of cancer, rising awareness regarding cure and treatment of cancer and increasing partnership between public and private areas to offer innovative cancer therapy in the region. The incidence of various types of cancer is much more in developing countries which concentrate these regions as favorable locations to conduct clinical trials. Furthermore the cost of clinical research is less in these regions due to the accessibility of a vast population base and favorable government policies contributing to the cancer drugs market growth in the developing countries.

By Regional & Country Analysis:

North America

• U.S.
• Canada

Europe

• Germany
• France
• U.K.
• Italy
• Spain
• Sweden
• Netherland
• Turkey
• Switzerland
• Belgium
• Rest of Europe

Asia-Pacific

• South Korea
• Japan
• China
• India
• Australia
• Philippines
• Singapore
• Malaysia
• Thailand
• Indonesia
• Rest Of APAC

Latin America

• Mexico
• Colombia
• Brazil
• Argentina
• Peru
• Rest of South America

Middle East and Africa

• Saudi Arabia
• UAE
• Egypt
• South Africa
• Rest Of MEA